

BIOSCIENCE INNOVATION GRANTS GRANT REPORT 2021-2023

Agriculture Commissioner Doug Goehring

The North Dakota Legislature created a bioscience innovation grant program to support biotechnology innovation and commercialization in areas including crop genetics, biofuels, biomaterials, biosensors and biotechnology. A total of \$5.5 million in grant funding was awarded to projects to develop the bioscience industry in North Dakota for the 2021-2023 biennium.

10 grants awarded

\$5.5 million

Genovac Antibody Discovery

\$1.45 million to purchase enabling technology that will support the development and production of antibodies and other biological and agricultural products.

Lincoln Therapeutics, LLC

\$712,000 to develop intranasal ketamine as a safer, fast acting, non-addicting analgesic to improve battlefield pain management.

Krampade

\$200,000 to manufacture a high protein, high potassium powdered drink mix; a high protein, high fiber powdered drink mix and a high potassium bar.

CorVent Medical, Inc.

\$113,000 to incorporate new features into an existing ventilator product that can be built into a prototype for testing and validation. Following the prototype, CorVent Medical will build a product for FDA submission.

Bioscience Association of North Dakota

\$600,000 to bring entrepreneurs and innovators together with companies to form collaborations that will result in products that not only utilize raw materials from North Dakota but will result in commercialization of those products leading to the creation of new biotechnology industries in North Dakota.

SafetySpect Inc.

\$1 million to move from a minimum viable product beta unit to a commercial device for their Contamination Sanitation Inspection and Disinfection system.

Checkable Medical

\$300,000 to run a clinical study to support the first over-the-counter test for Strep A.

National Agriculture Genotyping Center

\$125,000 to upgrade the current biotechnology used for variety identification and certification of spring wheat and barley.

WoundExam Corp

\$100,000 to develop WoundAssure, a multi-mode imaging technology that will monitor changes in wounds in patients at high risk of complications from diabetic ulcers.

Agathos Biologics

\$900,000 to create new materials and methods for research and biomanufacturing and use them for drug development to address unmet medical needs and increase the availability of genetic medicines to more patients.



CARES ACT BIOSCIENCE INNOVATION GRANTS GRANT REPORT 2020

Agriculture Commissioner Doug Goehring

The CARES Act Bioscience Grant Fund was used to support biotechnology innovation and commercialization, promote the creation of bioscience jobs in the state, and promote bioscience research and development in North Dakota in the area of coronavirus research. A total of \$5 million in grant funding was awarded for these projects in 2020.

8 grants awarded

\$5 million

SafetySpect Inc.

\$1.5 million to develop and manufacture a contamination, sanitation inspection, and disinfection system for use in the food processing and service industry.

Checkable Medical

\$40,000 to generate clinical performance data to meet FDA criteria for their at-home Rapid Antibody Test through a study.

Biomed Protection ND

\$45,000 to produce peptides and test animal and human serum samples for the presence of anti-interferon antibodies.

Biomed Protection ND

\$1,422,200 to develop a platform based on electronic biology to allow rapid and accurate real-time monitoring of genetic changes to coronaviruses. Information gained is used to design proteins for production of vaccine candidates or immunotherapies.

Core Health Strategies

\$30,000 to address the ability to create a large source of bovine interleukin-10 (IL-10) which has application in the immune response in the human COVID-19 patient.

Core Health Strategies

\$50,000 to perform a 4 week natropathic supplantation program with the intent of protecting against SARS-CoV-2 infections in the supplemented population.

ImmunoPrecise Antibodies

\$1.5 million to formulate a therapeutic that retains efficiency, even as SARS-CoV-2 evolves.

Genovac Antibody Discovery

\$412,800 to develop SARS-CoV-2 antibodies and therapeutics for diagnostics and developed nanodisc-based vaccine candidates for active immunization, in collaboration with Harvard Medical School.